Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators

Open source

DOI: 10.1056/nejmoa2312054
Published: 2024 Jan 25
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2312054,
  title = {Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.},
  author = {Sonneveld P and Dimopoulos MA and Boccadoro M and Quach H and Ho PJ and Beksac M and Hulin C and Antonioli E and Leleu X and Mangiacavalli S and Perrot A and Cavo M and Belotti A and Broijl A and Gay F and Mina R and Nijhof IS and van de Donk NWCJ and Katodritou E and Schjesvold F and Sureda Balari A and Rosiñol L and Delforge M and Roeloffzen W and Silzle T and Vangsted A and Einsele H and Spencer A and Hajek R and Jurczyszyn A and Lonergan S and Ahmadi T and Liu Y and Wang J and Vieyra D and van Brummelen EMJ and Vanquickelberghe V and Sitthi-Amorn A and de Boer CJ and Carson R and Rodriguez-Otero P and Bladé J and Moreau P and PERSEUS Trial Investigators},
  year = {2024},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2312054},
  url = {https://doi.org/10.1056/nejmoa2312054}
}

RIS

TY  - JOUR
TI  - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
AU  - Sonneveld P
AU  - Dimopoulos MA
AU  - Boccadoro M
AU  - Quach H
AU  - Ho PJ
AU  - Beksac M
AU  - Hulin C
AU  - Antonioli E
AU  - Leleu X
AU  - Mangiacavalli S
AU  - Perrot A
AU  - Cavo M
AU  - Belotti A
AU  - Broijl A
AU  - Gay F
AU  - Mina R
AU  - Nijhof IS
AU  - van de Donk NWCJ
AU  - Katodritou E
AU  - Schjesvold F
AU  - Sureda Balari A
AU  - Rosiñol L
AU  - Delforge M
AU  - Roeloffzen W
AU  - Silzle T
AU  - Vangsted A
AU  - Einsele H
AU  - Spencer A
AU  - Hajek R
AU  - Jurczyszyn A
AU  - Lonergan S
AU  - Ahmadi T
AU  - Liu Y
AU  - Wang J
AU  - Vieyra D
AU  - van Brummelen EMJ
AU  - Vanquickelberghe V
AU  - Sitthi-Amorn A
AU  - de Boer CJ
AU  - Carson R
AU  - Rodriguez-Otero P
AU  - Bladé J
AU  - Moreau P
AU  - PERSEUS Trial Investigators
PY  - 2024
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2312054
UR  - https://doi.org/10.1056/nejmoa2312054
ER  -

APA

P, S., MA, D., M, B., H, Q., PJ, H., M, B., C, H., E, A., X, L., S, M., A, P., M, C., A, B., A, B., F, G., R, M., IS, N., NWCJ, V. D. D., E, K., F, S., A, S. B., L, R., M, D., W, R., T, S., A, V., H, E., A, S., R, H., A, J., S, L., T, A., Y, L., J, W., D, V., EMJ, V. B., V, V., A, S., CJ, D. B., R, C., P, R., J, B., P, M., & Investigators, P. T. (2024). Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2312054

Source records

pubmed · retrieved 2026-09-25T13:29:48.986Z